1707 related articles for article (PubMed ID: 25901682)
1. Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Kreiter S; Vormehr M; van de Roemer N; Diken M; Löwer M; Diekmann J; Boegel S; Schrörs B; Vascotto F; Castle JC; Tadmor AD; Schoenberger SP; Huber C; Türeci Ö; Sahin U
Nature; 2015 Apr; 520(7549):692-6. PubMed ID: 25901682
[TBL] [Abstract][Full Text] [Related]
2. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Sahin U; Derhovanessian E; Miller M; Kloke BP; Simon P; Löwer M; Bukur V; Tadmor AD; Luxemburger U; Schrörs B; Omokoko T; Vormehr M; Albrecht C; Paruzynski A; Kuhn AN; Buck J; Heesch S; Schreeb KH; Müller F; Ortseifer I; Vogler I; Godehardt E; Attig S; Rae R; Breitkreuz A; Tolliver C; Suchan M; Martic G; Hohberger A; Sorn P; Diekmann J; Ciesla J; Waksmann O; Brück AK; Witt M; Zillgen M; Rothermel A; Kasemann B; Langer D; Bolte S; Diken M; Kreiter S; Nemecek R; Gebhardt C; Grabbe S; Höller C; Utikal J; Huber C; Loquai C; Türeci Ö
Nature; 2017 Jul; 547(7662):222-226. PubMed ID: 28678784
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
4. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M; Kallinteris NL; von Hofe E
Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
6. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
7. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy: exploiting neoepitopes.
Platten M; Offringa R
Cell Res; 2015 Aug; 25(8):887-8. PubMed ID: 26032267
[TBL] [Abstract][Full Text] [Related]
9. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.
Yadav M; Jhunjhunwala S; Phung QT; Lupardus P; Tanguay J; Bumbaca S; Franci C; Cheung TK; Fritsche J; Weinschenk T; Modrusan Z; Mellman I; Lill JR; Delamarre L
Nature; 2014 Nov; 515(7528):572-6. PubMed ID: 25428506
[TBL] [Abstract][Full Text] [Related]
10. Exploiting the mutanome for tumor vaccination.
Castle JC; Kreiter S; Diekmann J; Löwer M; van de Roemer N; de Graaf J; Selmi A; Diken M; Boegel S; Paret C; Koslowski M; Kuhn AN; Britten CM; Huber C; Türeci O; Sahin U
Cancer Res; 2012 Mar; 72(5):1081-91. PubMed ID: 22237626
[TBL] [Abstract][Full Text] [Related]
11. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
[TBL] [Abstract][Full Text] [Related]
12. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
13. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
14. An immunogenic personal neoantigen vaccine for patients with melanoma.
Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
[TBL] [Abstract][Full Text] [Related]
15. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
16. Metadherin peptides containing CD4(+) and CD8(+) T cell epitopes as a therapeutic vaccine candidate against cancer.
Dhiman G; Lohia N; Jain S; Baranwal M
Microbiol Immunol; 2016 Sep; 60(9):646-52. PubMed ID: 27554419
[TBL] [Abstract][Full Text] [Related]
17. T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep.
Rojas JM; Rodríguez-Calvo T; Peña L; Sevilla N
Vaccine; 2011 Sep; 29(40):6848-57. PubMed ID: 21807057
[TBL] [Abstract][Full Text] [Related]
18. Identification of MHC class II-restricted tumor antigens recognized by CD4+ T cells.
Wang RF
Methods; 2003 Mar; 29(3):227-35. PubMed ID: 12725788
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
20. A bioinformatics tool for epitope-based vaccine design that accounts for human ethnic diversity: application to emerging infectious diseases.
Oyarzun P; Ellis JJ; Gonzalez-Galarza FF; Jones AR; Middleton D; Boden M; Kobe B
Vaccine; 2015 Mar; 33(10):1267-73. PubMed ID: 25629524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
